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Abstract
Background: We estimated U.S. biomedical research funding across therapeutic areas, determined the association with
disease burden, and evaluated new drug approvals that resulted from this investment.
Methodology/Principal Findings: We calculated funding from 1995 to 2005 and totaled Food and Drug Administration
approvals in eight therapeutic areas (cardiovascular, endocrine, gastrointestinal, genitourinary, HIV/AIDS, infectious disease
excluding HIV, oncology, and respiratory) primarily using public data. We then calculated correlations between funding,
published estimates of disease burden, and drug approvals. Financial support for biomedical research from 1995 to 2005
increased across all therapeutic areas between 43% and 369%. Industry was the principal funder of all areas except HIV/
AIDS, infectious disease, and oncology, which were chiefly sponsored by the National Institutes of Health (NIH). Total
(r= 0.70; P = .03) and industry funding (r= 0.69; P = .04) were correlated with projected disease burden in high income
countries while NIH support (r= 0.80; P = .01) was correlated with projected disease burden globally. From 1995 to 2005 the
number of new approvals was flat or declined across therapeutic areas, and over an 8-year lag period, neither total nor
industry funding was correlated with future approvals.
Conclusions/Significance: Across therapeutic areas, biomedical research funding increased substantially, appears aligned
with disease burden in high income countries, but is not linked to new drug approvals. The translational gap between
funding and new therapies is affecting all of medicine, and remedies must include changes beyond additional financial
investment.
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Introduction
Biomedical research in the United States has been the
beneficiary of investment by many public and private sources.
This investment reflects its importance to society, whether
measured by human suffering and the burden of disease or by
commercial and economic terms. Current total annual funding for
biomedical research in the U.S. is approximately $100 billion, and
over the past decade has tripled in nominal dollars and doubled
after adjusting for inflation [1,2]. However, the rise in funding has
not been mirrored by an increase in new therapies [2]. Within
each therapeutic area in medicine (e.g., oncology, cardiology), the
sources of funds, their relationship to disease burden, and the
number of recently developed therapies is generally not known.
Therefore, we sought to (1) estimate U.S. funding by therapeutic
area, (2) determine whether this funding is aligned with disease
burden, and (3) evaluate whether this investment has translated
into therapeutic advances. Comparing the productivity of
biomedical research across therapeutic areas will help guide and
inform private investments and public research policy [3,4].
Methods
Therapeutic Areas Examined
We selected based on available data and defined nine
therapeutic areas within medicine (cardiovascular, endocrine,
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gastrointestinal, genitourinary, HIV/AIDS, infectious disease
excluding HIV, neuroscience, oncology, and respiratory) based
on U.S. Bureau of Census Industrial Report product codes for
pharmaceutical preparations, except biologicals [5]. For neurosci-
ence, we used previously published data [6] but revised the
National Institutes of Health (NIH) funding estimates to exclude
HIV/AIDS research. With the exception of HIV/AIDS, each
therapeutic area was broad and included multiple medical
conditions. For example, funding for neuroscience included
funding directed at neurological disorders (e.g., stroke, Parkinson
disease), mental health (e.g., depression, schizophrenia), substance
abuse, and sensory organs besides skin.
Biomedical Research Funding by Therapeutic Area
National Institutes of Health. We allocated NIH funding
by assigning each Institute’s annual appropriation to a therapeutic
area (e.g. appropriations for the National Cancer Institute were
assigned to oncology) [7]. We allocated appropriations for
Institutes that covered multiple therapeutic areas based on
funding for disease divisions within each Institute, as outlined in
each Institute’s Congressional Budget Justification.
We quantified HIV/AIDS research support from Office of
AIDS Research Congressional Budget Justifications (1998–2005)
[8] and its budget office (1995–1997) (Wendy Wertheimer, Office
of AIDS Research Information Dissemination, historical data,
2007). We estimated infectious disease research funding excluding
HIV using appropriations for the National Institute of Allergy and
Infectious Disease and the John E. Fogarty International Center.
Cardiovascular research funding was estimated using monies
directed to ‘‘heart and vascular research’’ and ‘‘blood diseases and
resources’’ by the National Heart, Lung, and Blood Institute
(NHLBI) [9]. Respiratory research funding was estimated by
combining funding for ‘‘lung diseases’’ and ‘‘sleep disorders.’’ The
ratio of cardiovascular to respiratory NHLBI research funding was
applied to the balance of NHLBI appropriations for each year to
distribute proportionately all remaining funding between cardio-
vascular and respiratory research. Endocrine, gastrointestinal, and
genitourinary research funding were identified through appropri-
ations to the National Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK) [10] and its budget office (Chris Porter,
NIDDK Office of Financial Management and Analysis, historical
data, 2007).
Using this methodology, we categorized $8.1 (72%) of $11.3
billion in total NIH appropriations in 1995, and $20.2 (72%) of
$28 billion in total NIH appropriations in 2005. The remaining
research funding included appropriations to Institutes and Centers
without a clear link to a therapeutic area examined.
Pharmaceutical firms. We estimated domestic biome-
dical research funding from pharmaceutical firms using funding
data from the Pharmaceutical Research and Manufacturers of
America (PhRMA) for 1995–2000 [11–13] and from Thomson
CenterWatch thereafter [14]. PhRMA reports domestic research
and development expenditures stratified by U.S. Bureau of Census
Industrial Report product codes [5]. Cardiovascular and respiratory
research support were identified directly. The remaining product
codes were separated into more focused therapeutic areas based on
the value of shipments of pharmaceutical preparations within each
product code [5].
Because Thomson CenterWatch estimates included foreign
research and development expenditures, they were greater than
PhRMA’s totals (P. Dewberry, personal communication, Septem-
ber 6, 2006). To account for this disparity we conservatively
decreased Thomson CenterWatch estimates to the total domestic
research and development expenditures reported by PhRMA [15],
keeping the proportions across therapeutic areas constant. Data
for years 2001, 2003, and 2005, which were not reported by
Thomson CenterWatch, were interpolated linearly from neigh-
boring years. Thomson CenterWatch research expenditure
estimates were stratified into the same six product codes as the
PhRMA funding data, and the same methodology was used to
allocate funds into the nine therapeutic areas. Missing data (5 of 99
total cells) was estimated by linear interpolation from neighboring
years.
Biotechnology and medical device firms. We estimated
research and development expenditures by the 10 largest US-
based biotechnology and medical device firms that were not
members of PhRMA in 2005. We selected the top 10
biotechnology companies (Genentech, Gilead Sciences, Biogen
Idec, MedImmune, Celgene, ImClone, Medicis, ViroPharma,
Protein Design Labs, and Intermune) top 10 medical device firms
(Medtronic, Baxter, Tyco International, Boston Scientific, Becton
Dickinson, Stryker, Guidant, Zimmer, St Jude Medical, and
Biomet) based on their 2005 revenues using Standard Industry
Classification codes [16] and each firm’s financial reports [17].
We obtained research and development expenditures from each
firm’s Security and Exchange Commission filings [17] and used
several methods to estimate expenditures for each therapeutic
area. We first assigned each of a firm’s approved products to a
therapeutic area based on the product’s primary therapeutic
indication. When a firm’s financial report clearly defined its
research and development expenditures by product, we assigned
expenditures to therapeutic areas based on the product’s primary
therapeutic indication (n = 3 firms). If research and development
expenditures were not listed by product, we estimated each
product’s portion of research and development spending by taking
the ratio of product-specific revenues to total revenues and
applying this to total research and development expenditures
(n = 12). If neither research and development expenditures nor
total revenues were listed by product (n = 5), we then took the
product-specific proportion of revenue from the earliest year
available and applied this proportion to total research and
development spending for all previous years.
Not-for-profit organizations. Not-for-profit organizations
included foundations and voluntary health organizations. We
included the ten largest foundations that funded medical research
for each year 1998–2005 (total of 28 foundations over the course
of 8 years), as identified by Foundation Center [18], and ten
voluntary health organizations with the largest research
expenditures in 2004, as identified by Research!America [19].
We then examined research support from annual reports
(if available) or by contacting organizations directly. Of the 38
total not-for-profit organizations, 16 did not support research that
could be specifically assigned to therapeutic areas defined in this
study and 5 did not have data available (including the largest
foundation). Of the 17 remaining organizations, 11 had data for all
years and 6 had data available for only several years (mean of 3
years). Research funding for each organization was allocated to a
therapeutic area based on information provided by annual reports
[20–36].
Disease Burden
We obtained projected disease burden estimates, as measured in
disability-adjusted life years (DALYs), for both the world and high-
income countries from the World Health Organization Global
Burden of Disease report for 2015 [37,38]. WHO disease
categories were more focused than those in the U.S. Census
Bureau Industrial Report, and thus several categories (e.g.,
‘‘neuropsychiatric conditions’’ and ‘‘sense organ diseases’’) were
Biomedical Research Financing
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combined to match the defined therapeutic areas used here (e.g.,
neuroscience).
Therapeutic Outputs
We obtained the number of approved drugs directly from the
U.S. Food and Drug Administration (FDA) website [39]. We
assigned a therapeutic area to each new drug application approval
from 1995 through 2005, based on the U.S. Bureau of Census
pharmaceutical product codes [5,40–42]. We tabulated all new
drug application and all new molecular entities [40–42] approvals
for each of the therapeutic areas.
Statistical Analysis
We used the Biomedical Research and Development Price
Index to adjust spending to 2005 dollars [43]. To determine
whether funding in 2005 was aligned with disease burden, we used
SAS version 9.1 to calculate Spearman rank correlations between
total funding and disease burden for 2015 across therapeutic areas.
We used projected DALYs for 2015 as the primary metric because
research investments may take up to a decade or more to be
realized in the form of new treatments. Rank correlations between
2015 disease burden and major funding sources (NIH or industry)
were also calculated. To evaluate whether funding was associated
with FDA approvals, we calculated rank correlations between total
funding (for all therapeutic areas) in each year (e.g., 1995 funding)
and FDA approvals eight years hence (e.g., 2003 approvals), which
approximates the time to develop a drug once it enters clinical
testing [44]. Because an eight-year lag period is insufficient to
account for pre-clinical development where the majority of NIH
funding is directed [2], we also calculated rank correlations
between FDA approvals and industry funding alone (pharmaceu-
tical, biotechnology, and medical device firms). The a priori level
of significance used for correlations was 0.05 (without adjusting for
multiple comparisons).
Results
After adjusting for inflation, financial support for domestic
biomedical research from 1995 to 2005 increased between 43%
and 369% in the therapeutic areas examined (Table 1). Neuro-
science, oncology, and cardiovascular research received the largest
total funding and accounted for 57% of 2005 total research
expenditures in this analysis. Gastrointestinal and genitourinary
research funding experienced the greatest increase.
The pharmaceutical industry was the largest sponsor of research
across most therapeutic areas, ranging from 32% of oncology
research support to 80% of endocrine research in 2005
(Figures 1a–e and Figures 2a–e). However, NIH provided the
majority of support for HIV/AIDS (59%), infectious disease
(excluding HIV) (54%), and oncology (52%) research. Oncology
(42%) was the largest recipient of biotechnology funding, while
73% of medical device funding targeted cardiovascular disease.
Total funding in 2005 was correlated with projected 2015
disease burden in high income countries (r=0.70; P= 0.03) and
likely correlated with 2015 global disease burden, but the latter did
not reach traditional standards of statistical significance (r=0.65;
P= 0.06) (Figure 3a). Industry funding in 2005 was more strongly
aligned with 2015 disease burden in high income countries
(r=0.69, P= 0.04) than with global disease burden projections
(r=0.58; P= 0.10) (Figure 3b). Conversely, NIH funding was
more strongly aligned with 2015 global disease burden (r=0.80;
P= 0.01) than with disease burden in high income countries
(r=0.43; P = 0.25) (Figure 3c).
Across therapeutic areas, the number of total new approvals
from 1995 to 2005 generally was flat (Figures 1a–e, Figures 2a–e,
and Table 2). The number of approvals for new molecular entities
also did not increase substantially for any therapeutic area during
this time period (Table 3), and overall, approvals decline by 46%.
Higher total research funding was not associated with a higher
number of FDA approvals. Neither total (r=0.31; P= 0.42) nor
industry funding (r=0.48; P= 0.19) was correlated with total
approvals over a lag period of eight years.
Discussion
Like biomedical research as a whole, research funding within
the therapeutic areas examined adjusted for inflation doubled over
the past decade. The principal source (industry or NIH) of funding
varied by therapeutic area and research funding appeared to be
aligned with measures of disease burden. However, across
therapeutic areas, the increase in funding has not been
Table 1. Funding for Biomedical Research by Therapeutic Area, 1995–2005.
US $ in Billions
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Percent
change
Inflation-adjusted
percent change*
Neuroscience 4.8 5.5 6.5 7.6 7.3 7.7 9.0 10.2 11.3 12.6 13.6 184% 101%
Oncology 3.9 3.9 4.1 4.6 5.5 5.3 6.5 7.0 7.5 8.2 8.8 126% 60%
Cardiovascular 3.8 3.9 4.5 5.0 5.0 5.0 6.0 6.3 6.9 7.6 8.4 120% 56%
Endocrine 1.5 1.9 2.0 2.2 2.4 2.9 3.8 4.4 4.8 5.2 5.8 285% 172%
Infectious disease (excluding HIV) 2.0 2.2 3.1 3.1 2.1 2.7 3.2 3.5 4.5 5.1 5.4 168% 89%
HIV/AIDS 1.7 1.8 2.2 2.8 3.1 3.2 3.6 3.4 4.0 4.5 5.0 196% 110%
Gastrointestinal 0.4 0.6 0.6 0.7 0.8 0.9 2.0 3.3 3.8 3.4 2.9 562% 369%
Respiratory 1.1 1.3 1.3 1.1 1.3 1.2 1.6 1.7 1.8 2.1 2.2 102% 43%
Genitourinary 0.3 0.3 0.4 0.5 0.6 0.7 1.6 2.4 1.7 2.0 1.7 443% 284%
Total 19.5 21.4 24.8 27.5 28.0 29.6 37.3 42.1 46.4 50.7 53.8 175% 95%
Adjusted totala 27.6 29.5 33.2 35.7 35.3 36.0 43.7 47.8 50.7 53.4 53.8
*Adjusted for inflation by the Biomedical Research and Development Price Index.
doi:10.1371/journal.pone.0007015.t001
Biomedical Research Financing
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Figure 1. Research support, sponsors, and FDA new drug approvals from 1995 – 2005 for a) all therapeutic areas, b) neuroscience
research, c) oncology research, d) cardiovascular research, and e) endocrine research.
doi:10.1371/journal.pone.0007015.g001
Biomedical Research Financing
PLoS ONE | www.plosone.org 4 September 2009 | Volume 4 | Issue 9 | e7015
accompanied by an increase in the number of new therapies
available. Therefore, other factors must account for the mismatch
between investment and output, at least in drug development.
While industry funds the majority of research as a whole [2,19],
at least three therapeutic areas – HIV/AIDS, infectious disease
excluding HIV, and oncology – received the majority of their
Figure 2. Research support, sponsors, and FDA new drug approvals from 1995 – 2005 for a) infectious disease (non-HIV) research,
b) HIV research, c) gastrointestinal research, d) respiratory research, and e) genitourinary research.
doi:10.1371/journal.pone.0007015.g002
Biomedical Research Financing
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Figure 3. Correlation between a) total, b) industry, and c) NIH research funding in 2005 and projected disease burden in 2015 for
high income countries and the world.
doi:10.1371/journal.pone.0007015.g003
Biomedical Research Financing
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funding from the NIH. This finding reflects economic externalities
(influences, benefits or harms to third parties) that are not reflected
in markets [45]. These accrue in HIV/AIDS and other infectious
diseases, where research investment reflects concern for public
health. Political factors also influence public financing for these
conditions, as HIV and cancer have high visibility [46].
Biomedical research funding appeared to be aligned with
disease burden, at least in high-income countries. Previous
research has also found NIH funding to be correlated with disease
burden [3]. Unlike NIH funding, U.S. industry funding was
associated with disease burden in high-income countries but not
with global measures. The principal difference between NIH and
industry appears to be the differential funding of HIV/AIDS and
infectious diseases. While industry funding for infectious diseases
and HIV/AIDS is proportional to disease burden in high-income
countries, industry research funding is not on par with the global
burden of HIV/AIDS and other infectious diseases. This
discrepancy highlights the importance of public payers and
foundations, such as the Bill & Melinda Gates Foundation [47],
the Rockefeller Foundation [48], and others, whose funding
priorities reach beyond the U.S. boundaries.
While funding was correlated with disease burden, it was not
associated with an increase in new therapies, even when
incorporating a lag of eight years between funding and new drug
approvals. Probable explanations are longer and more complex
clinical trials and the associated additional cost of drug
development, with current estimates ranging from $600 million
to $1.2 billion [44,49]. Likewise, the introduction of the
development of large molecule biopharmaceuticals may have
increased the cost of drug development, but research suggests that
the costs of developing a biopharmaceutical are comparable to
those compounds produced by traditional pharmaceutical firms
[50]. New basic scientific knowledge also requires time before it is
ready for pre-clinical or clinical testing. Therefore, future
therapeutic advances may be forthcoming, and one study of the
drug development pipeline for Parkinson disease suggests that the
pipeline of available therapies is increasing [51]. However, the
declining trend in the number of new molecular entities is
worsening rather than improving. In 2007, the FDA approved 19
new drugs, the fewest in 24 years [52]. The increased funding and
absent rise of new drugs in all therapeutic areas adds to the
growing concerns about the productivity of biomedical research
[2,6,53,54] and underscore a need to examine non-economic
factors in the search for new treatments.
Economists [55] and historians of science [56] stress that
financial investment is but one of several elements that are
necessary for scientific progress. Other requirements include the
ready supply of talent (with relevant skill), favorable geography
(proximity of universities and companies), and a culture that
supports mobility between institutions (of people, ideas, and
Table 2. Total Number of Drugs Approved by US Food and Drug Administration by Therapeutic Area, 1995–2005.
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Neuroscience 14 31 18 15 14 15 16 19 16 19 12
Oncology 7 10 4 4 6 5 2 4 5 4 6
Cardiovascular 16 11 11 9 4 7 5 2 8 5 3
Endocrine 15 18 14 12 14 21 6 16 14 15 18
Infectious disease 14 25 19 17 12 13 10 12 9 12 15
HIV 4 4 4 3 3 5 1 2 5 3 4
Gastrointestinal 9 6 11 1 7 9 7 5 5 12 4
Respiratory 3 15 6 1 5 4 8 7 0 14 6
Genitourinary 2 3 4 2 0 1 3 2 2 3 0
Total 84 123 91 64 65 80 58 69 64 87 68
doi:10.1371/journal.pone.0007015.t002
Table 3. New Molecular Entities Approved by US Food and Drug Administration by Therapeutic Area, 1995–2005.
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Neuroscience 4 9 7 6 6 6 5 4 1 6 1
Oncology 3 6 3 2 4 3 1 2 3 4 3
Cardiovascular 9 4 7 7 2 3 3 2 2 1 0
Endocrine 3 5 6 1 3 5 3 0 3 2 6
Infectious disease 2 7 4 2 5 2 3 3 3 3 3
HIV 2 3 3 2 1 1 1 0 3 0 1
Gastrointestinal 2 1 2 0 2 4 0 3 3 1 0
Respiratory 1 4 0 1 2 0 2 0 0 1 0
Genitourinary 0 2 1 1 0 0 2 1 1 3 0
Total 26 41 33 22 25 24 20 15 19 21 14
doi:10.1371/journal.pone.0007015.t003
Biomedical Research Financing
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material). These factors have been recognized by the NIH,
foundations, and companies as priorities equal to additional
investment [57] and non-financial factors, such as exploring
partnerships between academia and industry, are receiving
growing attention in the scientific press [57,58]. The challenge is
to increase productivity, which is not commonly the focus of
scientists. Money, while necessary, is not sufficient to find new
drugs. Possible solutions to improving research productivity have
been offered and include decreasing the costs of clinical trials [59],
modifying the economic incentives that pharmaceutical companies
face (to favor high impact/high cost conditions) [60], increasing
the scale of research, open dissemination of negative results, and
reorganizing research enterprises to bring talent, instrumentation,
information, and material together in new ways [58,61,62].
Importantly, as demonstrated by recent experience, further
increases in the investment in research are probably inadequate,
unless they are complemented by such non-financial factors.
Our study focused on a narrow measure of output, new drug
approvals. While this metric is important and highly relevant to
the pharmaceutical industry, which funds most U.S. biomedical
research, other metrics may be more important to public health,
the economy, and science. For example, life expectancy in the
U.S. continues to increase, including for the decade 1990–2000
[63]. One large factor driving this increase is the reduction in
cardiovascular deaths with at least half this reduction attributable
to medical advances [63]. Economic research suggests that societal
gains from investment in research have been enormous and
advances that result in even modest reductions in cancer mortality
would more than justify substantial additional investments in
biomedical research [64]. In addition to the historical medical
advances, an indicator of more recent scientific advances is patent
activity. Research shows that the number of patents granted to
U.S. medical school faculty increased dramatically from 1981 to
2000 [65]. While the increase in patents and the economic
potential of additional therapeutic advances are promising, the
challenge is realizing this potential.
Our financial analysis was also limited by its geographic scope
and the data available. Our analysis was limited to the U.S.
Funding for biomedical research outside the U.S. is growing. For
example, PhRMA estimates that in 2008 research and develop-
ment abroad was $11.8 billion or 24% of total research and
development for its member companies. By comparison, in 2005
funding abroad was $3.3 billion and 22% of total [66]. Evaluating
global biomedical research funding, its trends, and relationship to
disease burden remain open areas for investigation. We were able
to tally funding from the two largest sponsors of U.S. biomedical
research that was directed toward one of the selected therapeutic
areas (over 84% of pharmaceutical industry funding and 70% of
NIH funding). However, not all funding is from one of the
principal sponsors and not all is directed toward a specific
therapeutic area. Consequently, we were able to account for
approximately half of all U.S. biomedical research funding ($46.4
billion of an estimated $94.3 billion in 2003) [2]. For the $48
billion that was outside the scope of this investigation, $27 billion
was from industry (principally biotechnology and medical device
industry) and could not be categorized by therapeutic area, $13
billion was from sources not included in this analysis (e.g., federal
sources outside the NIH, state and local governments, private
funds), $7 billion was from the NIH that is not targeted at a
particular therapeutic area (e.g., National Library of Medicine,
National Human Genome Research Institute), and approximately
$1 billion targeted therapeutic areas outside the scope of this paper
(e.g., dermatology). In addition, the data gathered were from
different sources that used various methods in their compilation.
However, the data do facilitate a comparison of funding across
therapeutic areas and an analysis of funding trends. Our funding
data was based on a convenience sample; therefore, our inferential
testing may be biased. For example, individuals who fund research
were not included in our analysis, and their funding priorities may
differ from those of industry or government.
With the exception of HIV/AIDS, we could not allocate
funding to a single disease. Thus the analyses, including
correlations between financing and disease burden and financing
and new drugs, performed are necessarily imperfect. In evaluating
disease burden, we relied on estimates from the World Health
Organization for DALYs as opposed to quality-adjusted life years,
which are frequently used in pharmacoeconomic analyses.
In conclusion, funding from the major U.S. research funders
across therapeutic areas in medicine has increased over the last
decade, is aligned with disease burden in high income countries,
but is not linked to the development of new medical therapies. Our
findings suggest that translating investment in biomedical research
into new therapies is becoming increasingly difficult across all
areas of medicine. Identifying means to either decrease the cost of
research or increase the output of new therapies will challenge all
those who invest in research, and these challenges will only grow
as funding constraints from industry [52] and governments [67]
become more apparent.
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